Expression of ribosome‐binding protein 1 correlates with shorter survival in Her‐2 positive breast cancer

Cancer Science

Xiaoshuan Liang¹  Shanshan Sun¹  Xianyu Zhang¹  Hao Wu¹  Weiyang Tao¹  Tong Liu¹  Wei Wei¹  Jingshu Geng² 

[1] Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China;Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China

关键词: Breast cancer;    Her‐2;    histological grade;    prognosis;    RRBP1;   

DOI  :  10.1111/cas.12666

来源: Wiley

【 摘 要 】

Abstract

The aim of this study is to investigate the expression of ribosome-binding protein 1 (RRBP1) in invasive breast cancer and to analyze its relationship to clinical features and prognosis. RRBP1 expression was studied using real-time quantitative PCR and western blotting using pair-matched breast samples and immunohistochemical staining using a tissue microarray. Then the correlation between RRBP1 expression and clinicopathologic features was analyzed. RRBP1 mRNA and protein expression were significantly increased in breast cancer tissues compared with normal tissues. The protein level of RRBP1 is proved to be positively related to histological grade (P = 0.02), molecular subtype (P = 0.048) and status of Her-2 (P = 0.026) and P53 (P = 0.015). We performed a grade-stratified analysis of all patients according to the level of RRBP1 expression and found that RRBP1 overexpression highly affected overall survival in patients with early-stage (I and II) tumors (P = 0.042). Furthermore, Her-2 positive patients with negative RRBP1 expression had longer overall survival rates than those with positive RRBP1 expression (P = 0.031). Using multivariate analysis, it was determined that lymph node metastasis (LNM, P = 0.002) and RRBP1 expression (P = 0.005) were independent prognosis factors for overall survival. RRBP1 is a valuable prognostic factor in Her-2-positive breast cancer patients, indicating that RRBP1 is a potentially important target for the prediction of prognosis.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.